Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study

N

National University Health System (NUHS)

Status

Not yet enrolling

Conditions

Cardiovascular Diseases
Non-Alcoholic Fatty Liver Disease
Metabolic Syndrome

Treatments

Behavioral: Digital wearable and AI-human symbiotic lifestyle intervention

Study type

Observational

Funder types

Other

Identifiers

NCT06211868
RESET

Details and patient eligibility

About

Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.

Enrollment

3,000 estimated patients

Sex

All

Ages

40 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 40-70 years old
  • ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher

Exclusion criteria

  • Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke)
  • Limited life expectancy
  • Other ongoing unstable medical conditions
  • Pregnant women

Trial design

3,000 participants in 2 patient groups

Observational cohort
Randomised cohort
Treatment:
Behavioral: Digital wearable and AI-human symbiotic lifestyle intervention

Trial contacts and locations

0

Loading...

Central trial contact

Hayang Yang, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems